Aankondiging • 2h
Integer Holdings Corporation to Report Q2, 2026 Results on Aug 06, 2026 Integer Holdings Corporation announced that they will report Q2, 2026 results at 9:30 AM, US Eastern Standard Time on Aug 06, 2026 Aankondiging • May 03
Integer Holdings Corporation Announces Earnings Guidance for the Year 2026 Integer Holdings Corporation announced earnings guidance for the year 2026. For the year, the company expects as reported sales in the range of $1,805 million to $1,835 million decrease of 3% to 1% as compared to previous year, operating income in the range of $165 million to $185 million decrease of 25% to 16% as compared to previous year, net income in the range of $105 million to $125 million increase of 2% to 21% as compared to previous year, and diluted earnings per share in the range of $3.07 to $3.64 increase of 6% to 26% as compared to previous year. Aankondiging • Apr 08
Integer Holdings Corporation, Annual General Meeting, May 20, 2026 Integer Holdings Corporation, Annual General Meeting, May 20, 2026. Location: hilton dallas/plano granite park hotel, 5805 granite parkway, plano, plano United States Aankondiging • Apr 07
Integer Holdings Corporation Announces Pamela G. Bailey, Independent Chair of the Board Will Not Stand for Re-Election At 2026 AGM Integer Holdings Corporation announced Pamela G. Bailey, who currently serves as Integer’s independent Chair of the Board, will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders, scheduled for May 20, 2026. Aankondiging • Apr 02
Integer Holdings Corporation to Report Q1, 2026 Results on Apr 30, 2026 Integer Holdings Corporation announced that they will report Q1, 2026 results Pre-Market on Apr 30, 2026 Aankondiging • Mar 12
Integer Holdings Corporation Announces Board Changes, Effective March 12, 2026 Integer Holdings Corporation has appointed two new directors to its Board of Directors: James F. Flanagan and Aaron Kapito. These appointments are effective as of March 12, 2026, and the board size has been increased to 13 members. The Cooperation Agreement also stipulates that two incumbent directors will not stand for re-election at the 2026 Annual Meeting of Stockholders. The agreement includes provisions for the appointment of the new directors to specific board committees, including the Audit Committee, the Compensation and Organization Committee, and the Technology Strategy Committee. The Cooperation Agreement includes voting commitments, standstill restrictions, and mutual non-disparagement provisions, which remain in place until the earlier of 30 days prior to the advance notice deadline for the 2027 Annual Meeting or one year from the effective date of the agreement. Mr. Flanagan is the former Chief Operating Officer of PwC from 2014 to 2021, bringing proven diversified, strategic, operational and qualified financial expertise through 39 years of increasing client and management roles. Previously, he also served as PwC’s US Financial Services Practice Leader from 2006 to 2014, and prior to that as the Transaction Services Leader from 2001 to 2006 and Transaction Services Partner from 1994 to 2001. He has served on the Board of Directors at Belami Ecommerce, a subsidiary of SkyX Platforms Corp. from 2022 to 2025, while also serving as Audit Committee Chair. Mr. Flanagan received a B.S. in Accounting from the C.W. Post School of Professional Accountancy at Long Island University. Mr. Kapito is a Partner at Politan Capital Management L.P., an investment management firm that he co-founded in 2021. Previously, Mr. Kapito served as a Senior Analyst at Lion Point Capital from 2018 to 2021, a Senior Analyst and founding member of Delonix Capital from 2016 to 2017, and an Associate Portfolio Manager for Elliott Management L.P. from 2011 to 2016. Mr. Kapito currently serves on the boards of Rocky Mountain Steel Mills, a manufacturer of high-performance steel products, and Associated Veterinary Partners, a veterinary clinic platform. Mr. Kapito received a B.S. in Economics from the Wharton School at the University of Pennsylvania and an M.B.A. from Harvard Business School. Aankondiging • Feb 19
Integer Holdings Corporation Provides Earnings Guidance for the Year 2026 Integer Holdings Corporation provided earnings guidance for the year 2026. For the year, the company expects as reported sales in the range of $1,826 million to $1,876 million, operating income in the range of $184 million to $204 million, net income in the range of $121 million to $138 million, and diluted earnings per share in the range of $3.53 to $4.01. Aankondiging • Jan 28
Integer Holdings Corporation to Highlight Integrated R&D Solutions and Expanded Coating Capabilities During Md&M West 2026 Integer Holdings Corporation will exhibit during MD&M West 2026 in Anaheim, Calif., Feb. 3 - 5. Integer will unveil a significantly expanded 20 x 50 sq. ft. new booth #3201, showcasing the company's full range of customer solutions. On prominent display will be R&D Velocity, Integer's integrated R&D ecosystem connecting design, prototyping and manufacturing to help medical device companies develop products that are manufacturable from the start, accelerating the time between design and manufacturability. The company will showcase several solutions - delivered through a network of locations globally - that are central to R&D Velocity, including: Differentiated Technology Platforms: Proven product technologies that enable, accelerate and de-risk the development of customers' next generation devices. Global Capabilities and Expertise: Specialized labs and integrated manufacturing all in one ecosystem along with dedicated engineers and global centers of excellence to accelerate every phase of development. Ease of Manufacturability: Designs optimized early to scale seamlessly, reducing rework and accelerating launch. Rapid Prototyping: Engineer-to-engineer collaboration delivering prototypes in as little as two weeks. Integer will additionally highlight a range of key product areas and innovations during MD&M West, including: Integer Medical Coatings: The company continues to expand its role as a fully integrated coating partner for medical devices, strengthening its ability to deliver end-to-end surface-modification solutions. Integer will also showcase its full coatings portfolio, including PTFE, PTFE alternatives, hydrophilic coatings, parylene, and advanced surface-modification technologies. Following the acquisitions of Precision Coating,VSi Parylene, and certain Biocoat assets last year, Integer has further strengthened its position as a fully integrated coating partner For medical devices. Cardiac Rhythm Management and Neuromodulation: Miniaturized technologies for finished IPG systems, as well as Gen 3 Li-Ion and Gen 2 CFx batteries. Cardio and Vascular: A full range of electrophysiology, structural heart, and neurovascular product solutions including complex catheters, guidewires, steerable introducers and sheaths, therapy delivery systems and implant technologies. Aankondiging • Jan 22
Integer Holdings Corporation to Report Q4, 2025 Results on Feb 19, 2026 Integer Holdings Corporation announced that they will report Q4, 2025 results Pre-Market on Feb 19, 2026 Aankondiging • Dec 11
Saxena White P.A. Files Securities Fraud Class Action Against Integer Holdings Corporation and Certain of its Executives Saxena White P.A. has filed a securities fraud class action lawsuit (the “Class Action”) in the United States District Court for the Southern District of New York against Integer Holdings Corporation (“Integer” or the “Company”) and certain of its executive officers (collectively, “Defendants”). The Class Action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and U.S. Securities and Exchange Commission (“SEC”) Rule 10b-5 promulgated thereunder on behalf of all persons or entities that purchased Integer common stock between July 25, 2024 and October 22, 2025, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Saxena White is captioned West Palm Beach Firefighters’ Pension Fund v. Integer Holdings Corporation, et al., No. 25-cv-10251 (S.D.N.Y.).Based in Plano, Texas, Integer purports to be one of the medical device contract development and manufacturing organizations in the world. The Company contracts with medical device companies to manufacture cardiac rhythm management and cardio and vascular (“C&V”) medical devices. Integer’s C&V product line generates approximately 60% of the Company’s total revenue. As a part of the C&V product line, Integer manufactures electrophysiology (“EP”) devices, which diagnose and map the heart’s electrical activity to address problems such as irregular heartbeats (cardiac arrhythmias).Prior to the Class Period, EP devices underwent a technological revolution as Integer customers began to develop devices for pulse field ablation (“PFA”) procedures that use brief, high-energy electrical pulses to treat atrial fibrillation. In turn, the industry became increasingly focused on integrating EP devices and PFA platforms to effectuate a more seamless cardiac procedure. As a result, EP devices represented a significant growth driver for Integer’s C&V segment. Leading up to the Class Period, CEO Dziedzic described PFA platforms as “a tailwind” due to the Company’s “vertically integrated offering[,]” while also touting that Integer “benefit[ed] significantly from electrophysiology procedure growth.” CEO Dziedzic further explained, “We participate in the full procedure, which is one of the strengths of Integer.” The Class Action alleges that, during the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose that: (1) Integer materially overstated its competitive position within the growing EP manufacturing market; (2) despite Integer’s claims of strong visibility into customer demand, the Company was experiencing a sustained deterioration in sales relating to two of its EP devices; (3) in turn, Integer mischaracterized its EP devices as a long-term growth driver for the Company’s C&V segment; (4) as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Aankondiging • Nov 05
Integer Holdings Corporation (NYSE:ITGR) announces an Equity Buyback for $200 million worth of its shares. Integer Holdings Corporation (NYSE:ITGR) announces a share repurchase program. Under the program, the company will repurchase up to $200 million worth of its common stock. The company intends to primarily utilize cash on hand and free cash flows to fund the share repurchase program. The program has no expiration date. Aankondiging • Sep 25
Integer Holdings Corporation to Report Q3, 2025 Results on Oct 23, 2025 Integer Holdings Corporation announced that they will report Q3, 2025 results Pre-Market on Oct 23, 2025 Aankondiging • Jul 11
Integer Holdings Corporation Appoints Michael Coyle to Board of Directors Integer Holdings Corporation announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee. He most recently served as president and CEO of iRhythm Technologies. Before that, he was executive vice president and group president of Medtronic’s cardio and vascular group and held leadership roles at St. Jude Medical and Eli Lilly earlier in his career. Coyle is currently a director on the Haemonetics Corporation and BaroPace boards and previously held positions on the boards of VNUS Medical Technologies Inc. and Volcano Corporation. He earned a master's degree in business administration from the Wharton School of Business, University of Pennsylvania, and a bachelor's degree from Case Western Reserve University. He additionally holds six U.S. patents related to cardiovascular medical device products and technologies. Aankondiging • Jun 26
Integer Holdings Corporation to Report Q2, 2025 Results on Jul 24, 2025 Integer Holdings Corporation announced that they will report Q2, 2025 results at 8:00 AM, US Eastern Standard Time on Jul 24, 2025 Aankondiging • Apr 25
Integer Holdings Corporation Provides Earnings Guidance for the Year 2025 Integer Holdings Corporation provided earnings guidance for the year 2025. For the year, the company expects sales in the range of $1,846 million to $1,880 million, Operating income in the range of $242 million to $258
million, Income from continuing operations of $108 million to $120 million, Diluted earnings per share in the range of $3.00 to $3.36. Aankondiging • Mar 27
Integer Holdings Corporation to Report Q1, 2025 Results on Apr 24, 2025 Integer Holdings Corporation announced that they will report Q1, 2025 results at 8:00 AM, Eastern Standard Time on Apr 24, 2025 Aankondiging • Mar 19
Integer Holdings Corporation, Annual General Meeting, May 21, 2025 Integer Holdings Corporation, Annual General Meeting, May 21, 2025. Location: 5830 granite parkway, suite 1150, plano, texas 75024, United States Aankondiging • Mar 13
Integer Holdings Corporation announced that it expects to receive $750 million in funding Integer Holdings Corporation announced a private placement that it will issue Convertible Senior Notes due 2030 in an aggregate principal amount of $750,000,000 on March 12, 2025. The Notes will be offered and sold only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The Company also expects to grant the initial purchasers of the Notes the option to purchase additional Notes in an aggregate principal amount of up to $125,000,000. In connection with the pricing of the Notes, the Company expects to enter into one or more privately negotiated capped call transactions with one or more of the initial purchasers or their affiliates or other financial institutions. Furthermore, in connection with the pricing of the Notes, the Company expects to enter into separate, privately negotiated transactions, with a limited number of holders of its 2.125% Convertible Senior Notes due 2028 to exchange a portion of Existing Convertible Notes for cash and shares of the Company’s common stock. In connection with any exchanges, the Company expects to terminate a portion of the existing option transactions entered into in connection with the issuance of the Existing Convertible Notes, in a notional amount corresponding to the amount of any Existing Convertible Notes exchanged. Aankondiging • Feb 05
Integer Holdings Corporation (NYSE:ITGR) acquired Substantially All Assets of Precision Coating Company, Inc. for approximately $150 million. Integer Holdings Corporation (NYSE:ITGR) acquired Substantially All Assets of Precision Coating Company, Inc. for approximately $150 million on January 7, 2025. A cash consideration of $152 million will be paid by Integer Holdings Corporation, subject to adjustment for additional contingent consideration. As part of consideration, $152 million is paid towards assets of Substantially All Assets of Precision Coating Company, Inc.
Integer Holdings Corporation (NYSE:ITGR) completed the acquisition of Substantially All Assets of Precision Coating Company, Inc. on January 7, 2025. Piper Sandler Companies (NYSE:PIPR) acted as financial advisor to Precision Coating Company, Inc. Aankondiging • Jan 23
Integer Holdings Corporation to Report Q4, 2024 Results on Feb 20, 2025 Integer Holdings Corporation announced that they will report Q4, 2024 results at 8:00 AM, US Eastern Standard Time on Feb 20, 2025 Reported Earnings • Oct 24
Third quarter 2024 earnings released: EPS: US$1.08 (vs US$0.82 in 3Q 2023) Third quarter 2024 results: EPS: US$1.08 (up from US$0.82 in 3Q 2023). Revenue: US$431.4m (up 6.6% from 3Q 2023). Net income: US$36.3m (up 33% from 3Q 2023). Profit margin: 8.4% (up from 6.7% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 14% per year. Buy Or Sell Opportunity • Oct 24
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 11% to €117. The fair value is estimated to be €97.30, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 16% in 2 years. Earnings are forecast to grow by 58% in the next 2 years. Buy Or Sell Opportunity • Oct 01
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 8.5% to €115. The fair value is estimated to be €95.28, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 17% in 2 years. Earnings are forecast to grow by 58% in the next 2 years. Aankondiging • Sep 27
Integer Holdings Corporation to Report Q3, 2024 Results on Oct 24, 2024 Integer Holdings Corporation announced that they will report Q3, 2024 results at 8:00 AM, US Eastern Standard Time on Oct 24, 2024 Buy Or Sell Opportunity • Aug 05
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 4.8% to €100.00. The fair value is estimated to be €125, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 17% in 2 years. Earnings are forecast to grow by 58% in the next 2 years. Recent Insider Transactions • Aug 02
Independent Director recently sold €509k worth of stock On the 31st of July, Jean Hobby sold around 5k shares on-market at roughly €111 per share. This transaction amounted to 67% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth €921k. Insiders have been net sellers, collectively disposing of €2.7m more than they bought in the last 12 months. Aankondiging • Jul 26
Integer Holdings Corporation Provides Earnings Guidance for the Year 2024 Integer Holdings Corporation provided earnings guidance for the year 2024. For the year, the company expects sales in the range of $1,735 million to $1,770 million, Operating income in the range of $202 million to $220 million, Net income in the range of $116 million to $130 million, Diluted earnings per share in the range of $3.26 to $3.67. Reported Earnings • Jul 26
Second quarter 2024 earnings released: EPS: US$0.93 (vs US$0.72 in 2Q 2023) Second quarter 2024 results: EPS: US$0.93 (up from US$0.72 in 2Q 2023). Revenue: US$436.2m (up 9.0% from 2Q 2023). Net income: US$31.2m (up 30% from 2Q 2023). Profit margin: 7.2% (up from 6.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 9% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • May 11
Senior Vice President of Strategy recently sold €525k worth of stock On the 7th of May, Andrew Senn sold around 5k shares on-market at roughly €105 per share. This transaction amounted to 52% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.0m more than they bought in the last 12 months. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: US$0.61 (vs US$0.39 in 1Q 2023) First quarter 2024 results: EPS: US$0.61 (up from US$0.39 in 1Q 2023). Revenue: US$414.8m (up 9.5% from 1Q 2023). Net income: US$20.5m (up 57% from 1Q 2023). Profit margin: 4.9% (up from 3.4% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has increased by 14% per year, which means it is well ahead of earnings. Aankondiging • Mar 29
Integer Holdings Corporation to Report Q1, 2024 Results on Apr 25, 2024 Integer Holdings Corporation announced that they will report Q1, 2024 results at 8:00 AM, US Eastern Standard Time on Apr 25, 2024 Board Change • Mar 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 6 highly experienced directors. Independent Director Sheila Antrum was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 16
Full year 2023 earnings released: EPS: US$2.72 (vs US$1.97 in FY 2022) Full year 2023 results: EPS: US$2.72 (up from US$1.97 in FY 2022). Revenue: US$1.60b (up 16% from FY 2022). Net income: US$90.7m (up 39% from FY 2022). Profit margin: 5.7% (up from 4.7% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Aankondiging • Feb 16
Integer Holdings Corporation Provides Earnings Guidance for the Year 2024 Integer Holdings Corporation provided earnings guidance for the year 2024. For the year, the company expects sales of $1,735 million to $1,770 million, operating income of $202 million to $220 million, net income of $115 million to $130 million and diluted earnings per share of $3.30 to $3.71. Aankondiging • Oct 28
Integer Holdings Corporation Provides Earnings Guidance for the Full Year of 2023 Integer Holdings Corporation provided earnings guidance for the full year of 2023. For the year, the company expects GAAP sales to be between $1,575 million to $1,595 million, 14% to 16% change from prior year. GAAP operating income to be between $166 million to $174 million, 36% to 43% change from prior year. GAAP net income to be between $90 million to $96 million, 37% to 48% change from prior year. GAAP diluted earnings per share to be between $2.66 to $2.86, 36% to 46% change from prior year. Aankondiging • Oct 27
Integer Holdings Corporation (NYSE:ITGR) acquired Certain Assets of InNeuroCo, Inc. Integer Holdings Corporation (NYSE:ITGR) acquired Certain Assets of InNeuroCo, Inc. on October 1, 2023. The acquisition is expected be immediately accretive to EPS.
Integer Holdings Corporation (NYSE:ITGR) completed the acquisition of Certain Assets of InNeuroCo, Inc. on October 1, 2023. Reported Earnings • Oct 27
Third quarter 2023 earnings released: EPS: US$0.82 (vs US$0.48 in 3Q 2022) Third quarter 2023 results: EPS: US$0.82 (up from US$0.48 in 3Q 2022). Revenue: US$404.7m (up 18% from 3Q 2022). Net income: US$27.3m (up 70% from 3Q 2022). Profit margin: 6.7% (up from 4.7% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Aankondiging • Sep 29
Integer Holdings Corporation to Report Q3, 2023 Results on Oct 26, 2023 Integer Holdings Corporation announced that they will report Q3, 2023 results at 8:00 AM, US Eastern Standard Time on Oct 26, 2023 Aankondiging • Sep 15
Jennifer M. Bolt Steps Down as Executive Vice President, Global Operations and ESG of Integer Holdings Corporation Integer Holdings Corporation announced that, at the request of the Company due to the restructuring of the position, Jennifer M. Bolt has stepped down as Executive Vice President, Global Operations and ESG, effective immediately. Ms. Bolt will remain with the Company until November 9, 2023, to support an effective transition of her responsibilities. Aankondiging • Jul 28
Integer Holdings Corporation Revises Earnings Guidance for the Year 2023 Integer Holdings Corporation revised earnings guidance for the year 2023. For the year, the company expects sales of $1,530 million to $1,550 million. Operating income of $152 million to $160 million. Net income of $83 million to $89 million. Diluted earnings per share of $2.45 to $2.65. Reported Earnings • Jul 28
Second quarter 2023 earnings released: EPS: US$0.72 (vs US$0.63 in 2Q 2022) Second quarter 2023 results: EPS: US$0.72 (up from US$0.63 in 2Q 2022). Revenue: US$400.0m (up 14% from 2Q 2022). Net income: US$24.0m (up 15% from 2Q 2022). Profit margin: 6.0% (in line with 2Q 2022). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 15% per year, which means it is well ahead of earnings. Aankondiging • Jun 30
Integer Holdings Corporation to Report Q2, 2023 Results on Jul 27, 2023 Integer Holdings Corporation announced that they will report Q2, 2023 results at 8:00 AM, US Eastern Standard Time on Jul 27, 2023 Recent Insider Transactions • Jun 16
Independent Director recently sold €283k worth of stock On the 9th of June, Jean Hobby sold around 4k shares on-market at roughly €77.96 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €314k more than they bought in the last 12 months. Reported Earnings • Apr 29
First quarter 2023 earnings released: EPS: US$0.39 (vs US$0.34 in 1Q 2022) First quarter 2023 results: EPS: US$0.39 (up from US$0.34 in 1Q 2022). Revenue: US$378.8m (up 22% from 1Q 2022). Net income: US$13.1m (up 15% from 1Q 2022). Profit margin: 3.4% (down from 3.7% in 1Q 2022). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Reported Earnings • Feb 18
Full year 2022 earnings released: EPS: US$1.97 (vs US$2.82 in FY 2021) Full year 2022 results: EPS: US$1.97 (down from US$2.82 in FY 2021). Revenue: US$1.38b (up 13% from FY 2021). Net income: US$65.4m (down 30% from FY 2021). Profit margin: 4.7% (down from 7.6% in FY 2021). Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 9% per year. Aankondiging • Feb 17
Integer Holdings Corporation Provides Earnings Guidance for the Year 2023 Integer Holdings Corporation provided earnings guidance for the year 2023. For the year, the company expects sales of $1,470 million to $1,500 million, operating income of $134 million to $145 million, net income of $71 million to $81 million and diluted earnings per share of $2.11 to $2.41. Aankondiging • Jan 31
Integer Holdings Corporation to Report Q4, 2022 Results on Feb 16, 2023 Integer Holdings Corporation announced that they will report Q4, 2022 results at 8:00 AM, US Eastern Standard Time on Feb 16, 2023 Recent Insider Transactions • Dec 17
President recently bought €234k worth of stock On the 16th of December, Joseph Dziedzic bought around 4k shares on-market at roughly €58.42 per share. This transaction amounted to 3.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Joseph's only on-market trade for the last 12 months. Recent Insider Transactions • Dec 02
Key Executive recently sold €69k worth of stock On the 30th of November, Jennifer Bolt sold around 1k shares on-market at roughly €69.00 per share. This transaction amounted to 3.9% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Jennifer's only on-market trade for the last 12 months. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: US$0.48 (vs US$0.67 in 3Q 2021) Third quarter 2022 results: EPS: US$0.48 (down from US$0.67 in 3Q 2021). Revenue: US$342.7m (up 12% from 3Q 2021). Net income: US$16.1m (down 27% from 3Q 2021). Profit margin: 4.7% (down from 7.2% in 3Q 2021). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 7% per year whereas the company’s share price has fallen by 5% per year. Aankondiging • Oct 28
Integer Holdings Corporation Provides Earnings Guidance for the Year 2022 Integer Holdings Corporation provided earnings guidance for the year 2022. For the year, the company expected sales of $1,350 million to $1,380 million; Operating income of $111 million to $127 million; Net income of $60 million to $73 million; and Diluted earnings per share $1.80 to $2.20. Aankondiging • Oct 12
Integer Holdings Corporation Announces Resignation of Joel Becker as President, Cardiac Rhythm Management & Neuromodulation Integer Holdings Corporation announced the resignation of Joel Becker as President, Cardiac Rhythm Management & Neuromodulation effective October 7, 2022. Valuation Update With 7 Day Price Move • Oct 11
Investor sentiment deteriorated over the past week After last week's 19% share price decline to €52.00, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 22% over the past three years. Recent Insider Transactions • Aug 17
Insider recently sold €196k worth of stock On the 12th of August, Carter Houghton sold around 3k shares on-market at roughly €72.30 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €724k more than they bought in the last 12 months. Reported Earnings • Jul 29
Second quarter 2022 earnings released: EPS: US$0.63 (vs US$0.89 in 2Q 2021) Second quarter 2022 results: EPS: US$0.63 (down from US$0.89 in 2Q 2021). Revenue: US$350.1m (up 12% from 2Q 2021). Net income: US$20.8m (down 29% from 2Q 2021). Profit margin: 6.0% (down from 9.4% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 9.9%, compared to a 7.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has remained flat whereas the company’s share price has fallen by 5% per year. Aankondiging • Jul 29
Integer Holdings Corporation Provides Earnings Guidance for the Fiscal Year 2022 Integer Holdings Corporation provided earnings guidance for the fiscal year 2022. For the period, the company expects sales to be in the range of $1,370 million to $1,395 million, Operating income to be in the range of $136 million to $148 million, Net income to be in the range of $83 million to $93 million and Diluted earnings per share to be in the range of $2.49 to $2.79. Aankondiging • Jul 01
Integer Holdings Corporation to Report Q2, 2022 Results on Jul 28, 2022 Integer Holdings Corporation announced that they will report Q2, 2022 results at 8:00 AM, US Eastern Standard Time on Jul 28, 2022 Aankondiging • Jun 26
Integer Holdings Corporation(NYSE:ITGR) dropped from Russell 2000 Dynamic Index Integer Holdings Corporation(NYSE:ITGR) dropped from Russell 2000 Dynamic Index Reported Earnings • Apr 29
First quarter 2022 earnings released: EPS: US$0.34 (vs US$0.65 in 1Q 2021) First quarter 2022 results: EPS: US$0.34 (down from US$0.65 in 1Q 2021). Revenue: US$310.9m (up 7.0% from 1Q 2021). Net income: US$11.4m (down 47% from 1Q 2021). Profit margin: 3.7% (down from 7.4% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 9.7%, compared to a 10% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 5% per year. Aankondiging • Apr 08
Integer Holdings Corporation (NYSE:ITGR) acquired Connemara Biomedical Holdings Teoranta for €130 million. Integer Holdings Corporation (NYSE:ITGR) acquired Connemara Biomedical Holdings Teoranta for €130 million on April 7, 2022. The consideration comprises of cash €120 million and an additional payment of €10 million of contingent consideration payable based on achievement of 2022 revenue growth milestones. The transaction was financed with borrowings under Integer’s existing revolving credit facility. Connemara Biomedical’s 130 associates will become the part of the Integer team. Connemara Biomedical generated sales of €15.59 million in 2021, nearly doubling sales from the prior year. The transaction is immediately accretive to Integer’s sales growth and profit margins.
Integer Holdings Corporation (NYSE:ITGR) completed the acquisition of Connemara Biomedical Holdings Teoranta on April 7, 2022. Buying Opportunity • Apr 06
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 2.1%. The fair value is estimated to be €88.86, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.5% over the last 3 years. Earnings per share has grown by 11%. Revenue is forecast to grow by 15% in 2 years. Earnings is forecast to grow by 60% in the next 2 years. Buying Opportunity • Mar 12
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 4.1%. The fair value is estimated to be US$88.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.5% per annum over the last 3 years. Earnings per share has grown by 11% per annum over the last 3 years. Reported Earnings • Feb 18
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: US$2.82 (up from US$2.35 in FY 2020). Revenue: US$1.22b (up 14% from FY 2020). Net income: US$93.0m (up 20% from FY 2020). Profit margin: 7.6% (up from 7.2% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 10.0%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Aankondiging • Feb 18
Integer Holdings Corporation Provides Sales Guidance for the First Quarter, Second Quarter and Second Half of 2022 Integer Holdings Corporation provided sales guidance for the first Quarter, Second Quarter and second half of 2022. The company expects Sales growth to be 10% to 12%, organic growth of 5% - 7%. and expects first Quarter of 2022 sales to be similar to fourth Quarter of 2021, constrained by COVID surge impact on labor and supply chain and expects second Quarter of 2022 sales to be better than first Quarter of 2022 from reduced impact of January’s COVID surge and supply chain volatility. The company anticipates strong second-half sales growth from improved labor, supply chain, and new product introductions. Recent Insider Transactions • Dec 12
Independent Director recently sold €91k worth of stock On the 7th of December, Jean Hobby sold around 1k shares on-market at roughly €75.96 per share. In the last 3 months, there was an even bigger sale from another insider worth €208k. Insiders have been net sellers, collectively disposing of €749k more than they bought in the last 12 months. Aankondiging • Dec 03
Integer Holdings Corporation (NYSE:ITGR) completed the acquisition of Oscor, Inc. from Thomas Osypka. Integer Holdings Corporation (NYSE:ITGR) entered into an agreement to acquire Oscor, Inc. from Thomas Osypka for approximately $220 million on October 27, 2021. Integer Holdings Corporation expects to finance the $220 million purchase price with debt. Oscor recognized $57 million sales in 2020. The transaction is subject to customary closing conditions. The transaction is expected to close in fourth quarter of 2021. The transaction is expect to be accretive to earnings per share in 2022 for Integer Holdings Corporation.
Integer Holdings Corporation (NYSE:ITGR) completed the acquisition of Oscor, Inc. from Thomas Osypka on December 2, 2021. Reported Earnings • Oct 29
Third quarter 2021 earnings released: EPS US$0.67 (vs US$0.92 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: US$305.6m (up 30% from 3Q 2020). Net income: US$22.1m (down 27% from 3Q 2020). Profit margin: 7.2% (down from 13% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Sep 17
Insider recently sold €208k worth of stock On the 14th of September, Joseph Flanagan sold around 3k shares on-market at roughly €78.76 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €412k more than they bought in the last 12 months. 
